Morgan Meredith A, Parsels Leslie A, Maybaum Jonathan, Lawrence Theodore S
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109-5637, USA.
Clin Cancer Res. 2008 Nov 1;14(21):6744-50. doi: 10.1158/1078-0432.CCR-08-1032.
In the last three decades, gemcitabine has progressed from the status of a laboratory cytotoxic drug to a standard clinical chemotherapeutic agent and a potent radiation sensitizer. In an effort to improve the efficacy of gemcitabine, additional chemotherapeutic agents have been combined with gemcitabine (both with and without radiation) but with toxicity proving to be a major limitation. Therefore, the integration of molecularly targeted agents, which potentially produce less toxicity than standard chemotherapy, with gemcitabine radiation is a promising strategy for improving chemoradiation. Two of the most promising targets, described in this review, for improving the efficacy of gemcitabine radiation are epidermal growth factor receptor and checkpoint kinase 1.
在过去三十年中，吉西他滨已从一种实验室细胞毒性药物发展成为一种标准的临床化疗药物和一种强效的放射增敏剂。为了提高吉西他滨的疗效，已将其他化疗药物与吉西他滨联合使用（无论是否联合放疗），但毒性已被证明是一个主要限制因素。因此，将可能比标准化疗产生更低毒性的分子靶向药物与吉西他滨放疗相结合，是一种有前景的改善放化疗效果的策略。本综述中描述的、用于提高吉西他滨放疗疗效的两个最有前景的靶点是表皮生长因子受体和检查点激酶1。
